10/23/2026
Understanding Obesity, Part 1: Is Your Doctor Measuring the Wrong Thing?
Every time you walk into a doctor’s office as a new patient, your height and weight are recorded. From those two numbers, your physician calculates your body mass index (BMI) and uses this number to determine if you’re healthy, overweight, or obese.
This formula was originally created in the 1830s by a mathematician, not a physician. The purpose was to define the “average man” and study human growth patterns, not measure health.
BMI cannot show your body fat percentage (how much of your body is fat) or lean muscle mass (how much of your body is muscle). Those two body composition metrics predict what diseases are forming inside you and what’s coming next with far greater accuracy than any scale.
The clinical threshold is clear – men above 25% body fat and women above 30% body fat. Cross those lines and the risk of disease is strikingly higher in breadth and severity.
The Tool Medicine Is Not Using
There is a documented clinical classification called metabolically obese normal weight (MONW). MONW describes an individual who has normal BMI but shows signs of disease that are usually tied to obesity.
Suppose a male patient has a BMI of 24, which is considered “normal weight.” His physician, using BMI alone, sees a healthy patient.
But the patient carries 29% body fat. By body composition standards, he is metabolically obese. His insulin resistance may already be progressing. But disease goes undetected because BMI doesn’t tell the whole story.
This is not rare. It happens in practices across the country every day because medicine isn’t looking at the right data.
What the Evidence Shows
Type 2 Diabetes
There is no chronic disease more directly linked to elevated body fat than type 2 diabetes. Excess adipose tissue, particularly visceral fat stored deep around your organs, leads to insulin resistance.
Your cells stop responding to insulin, blood glucose rises, and the pancreas compensates until it can’t keep up. Blood sugar stays high, causing the onset of type 2 diabetes.
Did you know:
Individuals with elevated body fat carry seven to 12 times the risk of developing type 2 diabetes.
80-90% of type 2 diabetics are overweight or obese by body composition standards.
Losing just 5-10% of body fat reduces the risk of progressing from pre-diabetes to full diabetes by 58%. This is just about as effective as prescription medication. intervention
Visceral fat, the most dangerous subtype, is invisible to BMI.
Heart Disease and Stroke
Cardiovascular disease is the leading cause of death globally. Elevated body fat percentage is one of the most powerful drivers of heart disease, but also the most modifiable through lifestyle change.
Excess body fat attacks the cardiovascular system in several ways at the same time:
Causes dyslipidemia (elevated triglycerides, low HDL, and dangerous, small, and dense LDL particles).
Activates the system that raises blood pressure.
Releases inflammatory molecules that damage arterial walls.
Deposits fat directly around the heart (epicardial fat) that independently predicts atrial fibrillation and coronary artery disease.
Did you know…
Obesity is linked to two to three times the risk of coronary heart disease.
Risk of ischemic stroke (when an artery to the brain is blocked by a blood clot or fatty plaque) increases by 1.5 to 2 times.
Risk of heart failure doubles.
The landmark Framingham Heart Study found that body fat distribution, not BMI, is stronger predictor of cardiovascular events like a heart attack or stroke.
A physician using medication to treat high cholesterol and blood pressure without measuring body fat percentage is treating downstream symptoms. Medication manages the number but the disease progresses because it goes unaddressed.
Cancer: The Connection Most People Don’t Know About
The World Health Organization and the American Cancer Society have confirmed that obesity increases the likelihood of at least 13 distinct cancers. It’s a direct cause, not a possible link.
The science is clear. Excess adipose tissue elevates insulin and IGF-1. These cellular growth signals promote tumor growth. High estrogen production leads to breast and endometrial cancers, while chronic inflammation allows cancer cells to survive and grow more effectively. Adiponectin, a natural anti-tumor molecule, is suppressed, eliminating one of the body’s natural defenses.
Consider the increased risk of different types of cancer due to obesity.
Endometrial: 200–400%
Esophageal adenocarcinoma: 200–300%
Kidney (renal cell): ~200%
Liver: ~200%
Pancreatic: ~50%
Colorectal: 30–50%
Postmenopausal breast: 20–50%
Gallbladder: 50–200%
Suppose a female patient with 34% body fat is carrying elevated estrogen, elevated insulin, elevated inflammatory markers, and suppressed adiponectin. Each is a documented cause of cancer. Without body composition measurement, the cancer risks are missed.
Osteoarthritis: More Than a Weight Problem
For years, joint disease in obese patients was explained mechanically. More weight means a heavier load to support and faster wear and tear on the joints. That is partially true.
But obesity-associated osteoarthritis also occurs in non-weight-bearing joints, including the hands and fingers, at high rates. The mechanical explanation doesn’t work here.
The root cause is systemic inflammation. Adipose tissue secretes molecules (leptin, resistin, TNF-alpha, IL-6) that break down cartilage throughout the body, not just in weight-bearing joints.
Did you know…
Obesity increases the risk of knee osteoarthritis by four to five times.
Hip osteoarthritis risk is approximately two times higher.
Every additional 10 pounds of body weight adds an estimated 30 to 60 pounds of force on the knee with each step, adding an enormous load to systemic inflammation.
The Real Failure
Medicine is not failing to treat these diseases. Failure to identify the root causes of diseases before they form is what ultimately kills people.
Body fat percentage and lean muscle mass can be measured. The tools exist (DEXA scans, clinical-grade bioelectrical impedance devices, etc.) and the research has been clear for decades. The problem is they’re not part of the standard intake process.
In Part 2 of this series on obesity, I’ll examine the full disease cascade, the economic cost of this gap, and what a new standard of care should look like.
This content is for educational purposes. Consult a qualified healthcare provider for personal medical guidance.
2. THE $1.72 TRILLION PROBLEM MEDICINE IS NOT SOLVING
2.0.1. Blog 2 of 2 | Natural Healthcare Center
In Part 1, we established the case: BMI — the tool medicine uses to screen for obesity — does not measure body fat. It measures weight relative to height. And the evidence is unambiguous that elevated body fat percentage, not elevated BMI, is the upstream driver of type 2 diabetes, heart disease, stroke, and at least 13 cancers.
But the disease burden does not stop there.
2.1. The Full Comorbidity Cascade
When body fat exceeds clinical thresholds — 25% in men, 30% in women — the downstream consequences extend across virtually every major chronic disease category.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Now the most common chronic liver condition globally. Driven by fat depositing directly in the liver. It progresses silently — often without symptoms — toward cirrhosis and liver cancer. Prevalence in obese individuals exceeds 70%.
Obstructive Sleep Apnea
Present in 40 to 70% of obese patients — most of it undiagnosed. Excess adipose tissue physically compresses the upper airway during sleep. The resulting oxygen deprivation at night activates the sympathetic nervous system, drives systemic inflammation, and compounds cardiovascular risk around the clock — not just during waking hours.
Chronic Kidney Disease
Obesity-related kidney disease is a well-established clinical entity. Obese individuals carry approximately 3 to 4 times the risk of end-stage renal disease. The two leading drivers of kidney failure — hypertension and type 2 diabetes — are both generated by excess adiposity. Medicine is treating the kidney. It is not always addressing what is destroying it.
Polycystic Ovarian Syndrome (PCOS)
Insulin resistance driven by excess body fat is a primary cause of the hormonal disruption, androgen excess, and infertility that define PCOS. Body fat percentage — not BMI — is the more accurate predictor of severity. Women with PCOS who reduce body fat frequently see measurable hormonal improvement without pharmaceutical intervention.
Depression and Cognitive Decline
The connection is biological, not merely psychological. The same inflammatory cytokines elevated in obesity — TNF-alpha, IL-6 — are the molecules most consistently implicated in major depressive disorder. Elevated visceral fat in midlife is an independent risk factor for dementia. The brain is not insulated from what the body’s adipose tissue is doing.
2.2. The Economic Argument
The clinical case alone is compelling. The economic case is staggering.
The total annual economic burden of obesity in the United States — direct medical costs plus lost productivity — is estimated at $1.72 trillion, approximately 9.3% of GDP
Direct medical costs attributable to obesity exceed $260 billion annually
An obese individual incurs on average $1,861 more per year in medical costs than a healthy-weight individual — a gap that compounds across a lifetime
Type 2 diabetes costs the US healthcare system approximately $327 billion per year, with the majority of that burden driven by obesity-related onset
Cardiovascular disease costs exceed $363 billion annually in direct and indirect costs
Obesity-attributable cancers contribute to a $200 billion annual cancer treatment burden
Now consider the other side of that equation.
A DEXA scan — the gold standard for body composition measurement — costs between $50 and $150. A clinical-grade bioelectrical impedance analysis (BIA) device costs a physician’s practice a few hundred dollars and delivers results in minutes.
The cost of identifying a patient as clinically obese by body fat standards at first intake, before downstream disease develops: less than $150.
The cost of treating the type 2 diabetes, cardiovascular events, joint replacements, and cancer that follow an undetected decade of elevated adiposity: hundreds of thousands of dollars per patient.
This is not a complicated equation. It is a prevention failure with a measurable price tag.
2.3. What the Standard of Care Should Look Like
The evidence compels a straightforward change. Every new patient intake should include:
Body fat percentage measurement
Lean muscle mass measurement
Visceral fat assessment where available
This matters clinically for four reasons:
It identifies risk early. Body fat percentage becomes pathological before blood glucose, cholesterol, and blood pressure do. Catching it first means the physician is working upstream — before the downstream numbers become crises.
It creates a trackable clinical variable. Adiposity is modifiable. Lean mass is buildable. Both can be remeasured at every subsequent visit. Progress becomes visible, objective, and motivating.
It changes the conversation. Grounding the obesity discussion in a clinical number — not in appearance, weight, or BMI — removes stigma and introduces precision. The patient is not being told they look unhealthy. They are being shown a measurement and a trajectory.
It reframes obesity correctly. Not as a lifestyle observation. Not as one risk factor among many. As a primary comorbidity — the upstream driver from which most of the chronic disease burden flows — and therefore the first thing a treatment plan must address.
2.4. The Argument in Plain Terms
A person above 25% body fat — if male — or 30% body fat — if female — is simultaneously carrying elevated risk for type 2 diabetes, heart disease, stroke, thirteen or more cancers, liver disease, kidney disease, sleep apnea, osteoarthritis, depression, and cognitive decline.
Not some of those conditions. All of them. At the same time. From the same upstream driver.
And yet the standard of care in traditional medicine does not measure that driver. It measures weight relative to height. It hands the patient a number invented in the 1830s by a mathematician. And it sends them home.
The current failure is not an evidence failure. Medicine has known for decades that body fat percentage is a superior predictor of metabolic disease risk. It has simply not changed the intake protocol to reflect that knowledge.
The evidence demands better. Our patients deserve better.
And the standard of care must finally reflect what the science has been telling us for years.
Natural Healthcare Center specializes in functional medicine, chiropractic care, nutrition, and body composition assessment. To schedule a consultation, contact our office at 732-222-2219
This content is for educational purposes. Consult a qualified healthcare provider for personal medical guidance.